Remogliflozin etabonate

From Self-sufficiency
Jump to: navigation, search
Remogliflozin etabonate
File:Remogliflozin etabonate structure.svg
Systematic (IUPAC) name
5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
Clinical data
Routes of
administration		 Oral
Identifiers
CAS Number 442201-24-3
ATC code none
Chemical data
Formula C26H38N2O9
Molar mass 522.586 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Remogliflozin etabonate (INN/USAN)[1] is a proposed drug for the treatment of type 2 diabetes being investigated by GlaxoSmithKline.[2] It did not undergo further development after phase II.[citation needed]

Method of action

Remogliflozin inhibits the sodium-glucose transport proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
Insulin
Meglitinides/"glinides"
Analogs/other insulins
Other
Amylin analog
SGLT2 inhibitors
Canagliflozin† · Dapagliflozin† · Remogliflozin† · Sergliflozin†
Other


45px This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it.
  1. ↑ Statement on a nonproprietory name adopted by the USAN council
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. ↑ Prous Science: Molecule of the Month November 2007
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Remogliflozin_etabonate&oldid=23585"